Search - tctmd.com

Displaying 561 - 580 of 589

Sort: Relevancy | Date

News Daily News

Could Biased Medication Prescribing Explain Obesity Paradox in PCI?

L.A. McKeown

May 19, 2016

News Daily News

Does the Atherosclerotic Cardiovascular Disease Calculator Overestimate Patient Risk? The Debate Continues

Yael L. Maxwell

May 04, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

Michael O'Riordan

January 28, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Michael O'Riordan

December 08, 2015

News Daily News

研究表明他汀类药物治疗会降低流感疫苗的有效性

Yael L. Maxwell

November 03, 2015

News Daily News

Statin Therapy Reduces Influenza Vaccine Effectiveness, Studies Suggest

Yael L. Maxwell

November 03, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Daily News

Cardiac Rehab After Acute MI Linked to Improved Survival, Medication Adherence

Leah Lawrence

August 30, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

August 06, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

Advertisement

Could Biased Medication Prescribing Explain Obesity Paradox in PCI?

Does the Atherosclerotic Cardiovascular Disease Calculator Overestimate Patient Risk? The Debate Continues

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

研究表明他汀类药物治疗会降低流感疫苗的有效性

Statin Therapy Reduces Influenza Vaccine Effectiveness, Studies Suggest

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

Cardiac Rehab After Acute MI Linked to Improved Survival, Medication Adherence

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content